2026-07-08T18:30:00.000Z
Why the AI in Genomics Market's 46.0% CAGR Is Favoring Software Over Hardware
A 46.0% compound annual growth rate looks like an unambiguous buy signal. Drill into how that growth splits between hardware and software, and the picture gets less comfortable for anyone who just bought a GPU cluster expecting to own the value chain. Kaiso Research's primary dataset puts the global AI in genomics market at $1,061.32 million in 2024, climbing to $68,191.11 million by 2035. That trajectory is not evenly distributed.
Software, not the accelerators underneath it, is the segment doing most of the work, and vendors positioning themselves purely as hardware suppliers are about to find out what that means for margin. This matters now because three of genomics' highest-profile 2025 announcements, an Illumina-NVIDIA collaboration, a QIAGEN acquisition, and a new variant-prediction model out of Google DeepMind, all point the same direction: the interpretation layer is consolidating faster than the sequencing layer beneath it. For biotech CIOs and product leaders at sequencing vendors, the question is no longer whether to adopt AI in genomics. It's which layer of the stack to own before someone else does.
Why a $1.06 Billion Base Compounds Roughly Every 22 Months Through 2035
A market growing at 46.0% annually doubles in size roughly every 22 months, meaning the global AI in genomics market, which Kaiso Research valued at $1,061.32 million in 2024, will have doubled several times before the 2035 forecast horizon ends. That compounding reflects three structural forces converging at once.
Next-generation sequencing has pushed genomic data volume past what manual interpretation can process, forcing labs and pharmaceutical research teams toward automated variant calling and functional annotation. Multi-omics integration, the practice of analyzing genomic, transcriptomic, proteomic, and metabolomic data together rather than in isolation, is shifting from a research luxury to a standard precision medicine workflow. And the hardware layer, GPUs, TPUs, and purpose-built inference accelerators, has matured enough to make real-time interpretation of massive reference panels routine rather than exceptional.
Kaiso Research's primary dataset across this vendor landscape identifies software as the dominant component segment, ahead of hardware, because software is what manages, interprets, and visualizes the genomic datasets sequencing instruments generate. Machine learning is the only technology category the report tracks, and genome sequencing is the largest functionality segment within it. Drug discovery and development is the application segment Kaiso flags as accelerating fastest, a detail that matters more than it sounds once it is connected to where biopharma capital is actually flowing in 2025 and 2026.
Illumina and NVIDIA Just Showed Every Sequencer Vendor Where the Margin Moves
Illumina and NVIDIA's January 2025 collaboration is the clearest signal yet that sequencing hardware vendors see their future in the AI layer, not the instrument. The two companies are combining Illumina's DRAGEN-powered multiomics platform with NVIDIA's BioNeMo generative AI models, RAPIDS accelerated data science tools, and MONAI imaging framework, with the first phase focused on running Illumina's DRAGEN algorithms directly on NVIDIA GPUs. Illumina already builds its own AI tools, including SpliceAI, PrimateAI-3D, and Emedgene, so the NVIDIA tie-up is less about filling a capability gap than about distribution and compute scale.
NVIDIA's accelerator stack was not standing still before that deal. Clara Parabricks, NVIDIA's existing genomics suite, already delivers GPU-accelerated secondary analysis built on BWA-MEM, GATK, and DeepVariant, the open-source variant caller Google originally developed for its own genomics research. NVIDIA's own platform materials describe whole genome sequencing analysis running over 100 times faster on Parabricks than on CPU-only pipelines, which is the performance baseline the Illumina partnership now extends into multiomics interpretation rather than secondary analysis alone.
QIAGEN is making the same bet from the software side. In 2024, QIAGEN shipped an AI-driven biomedical knowledgebase and an AI-enhanced version of QIAGEN Clinical Insight Interpret, the product line that anchors its clinical decision support business. In November 2025, QIAGEN agreed to acquire Parse Biosciences to push that portfolio into single-cell AI biology, a market QIAGEN's own disclosures put at roughly $1.2 billion in 2024 on its way to about $2.1 billion by 2029.
None of that figure comes from Kaiso Research's dataset, and it should not be read as a substitute for it. It is QIAGEN's own characterization of an adjacent market it just bought its way into.
Thermo Fisher Scientific, Deep Genomics, Insilico Medicine, GNS Healthcare, Fabric Genomics, and BioSymetrics round out the vendor landscape Kaiso Research tracks for this segment, and each occupies a narrower lane than the headline deals suggest. Thermo Fisher anchors instrumentation and reagents. GNS Healthcare works in causal machine learning applied to clinical outcomes data. Fabric Genomics builds clinical variant interpretation software for diagnostic labs.
BioSymetrics focuses on multi-omics data integration tooling rather than sequencing or drug discovery. Deep Genomics and Insilico Medicine, by contrast, have spent 2025 and 2026 building toward foundation-model platforms instead of point solutions, which is the trend the next section covers.
Four Forces Behind the 46.0% CAGR, and Why More Sequencing Data Is Only One of Them
More sequencing data explains part of the 46.0% CAGR Kaiso Research forecasts through 2035, but three other forces are doing at least as much work. The first is the sheer scale mismatch between sequencing throughput and human review capacity: as next-generation sequencing costs keep falling, the resulting data volume has outrun what bioinformatics teams can interpret manually, making automated variant calling and annotation a requirement rather than a convenience. Illumina's own published cost trajectory shows the scale of that mismatch: a genome that cost roughly $1 million to sequence in 2007 fell to about $20,000 by 2010, $1,000 by 2015, and around $200 today, multiplying the number of genomes a lab can afford to run far faster than any genomics department can scale its interpretation headcount. At 46.0%, this market compounds faster than most capital-equipment budgets get reviewed, which is exactly why hardware vendors are racing to attach themselves to a software layer instead of competing against it.
The second force is the maturity of the hardware-software pairing itself. GPU, TPU, and ASIC acceleration used to be a research advantage; now it is table stakes, and the differentiator has shifted to explainable AI frameworks that make pathogenicity predictions defensible to regulators and clinicians, not just accurate in a benchmark. The third force is regulatory and reimbursement momentum: regulators have begun introducing AI-enhanced companion diagnostics into clinical trial design, and reimbursement frameworks that recognize the cost-effectiveness of targeted therapies are pulling adoption into hospital networks and diagnostic labs faster than a purely technical reading of the market would predict.
The fourth force is platform consolidation through strategic partnerships, the same pattern visible in the Illumina-NVIDIA collaboration. When a pharmaceutical company and an AI vendor co-develop a genomics suite rather than buying point tools separately, the partnership tends to standardize data formats and reduce integration friction across the entire pipeline, which compounds the other three forces rather than sitting alongside them.
AlphaGenome, REPRESS, and the Race to Model the Genome at Base-Pair Resolution
Google DeepMind's AlphaGenome, launched in June 2025 and published in Nature in January 2026, is the clearest technical marker of where genomic AI is heading: a single model that takes up to one million base pairs of DNA sequence as input and predicts thousands of molecular properties, including gene expression, splicing, and chromatin accessibility, at single-base-pair resolution. By the January 2026 Nature publication, nearly 3,000 scientists across 160 countries had already adopted the non-commercial API, and DeepMind opened the model's underlying source code and weights to the research community that same month, well ahead of any deployed clinical product. The model arrives as population-scale sequencing efforts are already generating more variants than manual curation can triage: the UK Biobank's own DRAGEN-based analysis of 500,000 whole genomes turned up 1.5 billion variants in a single study.
Deep Genomics moved in a related direction in May 2025 with REPRESS, a foundation model added to its BioFM platform that predicts microRNA binding and messenger RNA degradation directly from RNA sequence, an area of post-transcriptional biology that earlier tools largely missed.
A third trend sits further downstream from research labs entirely: consumer-facing genomic interpretation. Nucleus Genomics raised a $14 million Series A in January 2025, backed by Founders Fund and Alexis Ohanian's Seven Seven Six, to expand direct-to-consumer genetic testing that screens for more than 800 conditions from a single saliva sample. That round is small next to the billion-dollar pharma deals elsewhere in this market, but it signals venture capital is willing to fund genomic AI interpretation outside the hospital and the research lab, not just inside them.
Why 1 Million Base Pairs of Context Beats a Faster GPU
The technical differentiator separating winning genomics AI platforms from the rest is context window, not raw throughput. AlphaGenome's architecture, a U-Net-style design layered with a transformer backbone, processes DNA sequence across that one-million-base-pair window precisely because regulatory elements controlling a gene can sit far upstream or downstream of the variant being scored. A model that only sees a narrow band around a mutation will miss those distant regulatory effects entirely, no matter how fast the chip running it happens to be.
This is also where transformer architectures and graph neural networks earn their place in genomics specifically. They are built to model long-range sequence dependencies, three-dimensional chromatin interactions, and epigenetic modifications that simpler convolutional models cannot capture at scale, which is why the multi-omics reference datasets training these systems are producing genuinely higher accuracy on variant effect prediction and gene-expression imputation rather than marginal gains. None of that compute advantage matters clinically, though, without an explainable AI layer on top. A prediction a clinician cannot trace back to a defensible rationale does not survive contact with a hospital's compliance review, regardless of its benchmark accuracy.
Illumina's own PromoterAI follows the same context-over-throughput logic at a narrower scale. Published in Science, the deep learning model focuses specifically on noncoding promoter regions and lifted diagnostic yield in rare disease cohorts by as much as 6%, a gain a context-blind, throughput-only pipeline would have had no way to surface.
Illumina Owns the Sequencer. Google Owns the Model. Who Owns the Patient?
Four distinct competitive positions are forming inside this market, and they are not converging toward one model. Illumina and NVIDIA are betting on vertical integration: own the sequencing instrument and the inference layer running on top of it, so the customer never has to choose a separate AI vendor. QIAGEN is betting on acquisition-led specialization instead, building out a clinical decision support and single-cell analysis portfolio without owning a sequencer at all.
Google DeepMind is staking out a third position entirely: open, non-commercial research infrastructure that other companies will eventually build commercial products on top of, rather than a product Google sells directly into clinics today. Insilico Medicine occupies a fourth lane, applying genomics-informed AI to drug discovery rather than diagnostics, a distinction that matters because its revenue model runs on pharma milestone payments, not instrument or software sales.
The vendors who control both the sequencing instrument and the inference layer will set pricing for everyone else in this market within the next two product cycles. Pure-play bioinformatics software companies without an instrument or compute partner are negotiating from a weaker position than their feature lists suggest, no matter how strong their explainable AI module is on its own merits.
Insilico's $2.5 Billion SK Biopharmaceuticals Deal Is a Genomics AI Story Too
Capital is moving toward this market from two directions that do not look like each other at all. Insilico Medicine completed Hong Kong's largest biotech IPO of 2025 on December 30, 2025, raising HKD 2.277 billion, then followed with a deal worth up to $2.75 billion with Eli Lilly in March 2026 and a deal worth up to $2.5 billion with SK Biopharmaceuticals in June 2026 applying its genomics-informed target identification platform to neuroimmune drug discovery. Both pharma deals are structured around milestone payments stretched across years, not upfront cash.
Nucleus Genomics' $14 million Series A is a far smaller number on the consumer end, but it represents capital betting on a different customer entirely: individuals paying out of pocket for genomic interpretation rather than hospitals or pharmaceutical R&D departments. QIAGEN's move into single-cell AI biology through the Parse Biosciences acquisition sits between those two poles. The thesis emerging from all three: capital has limited patience for pure infrastructure plays in the middle of the stack and is concentrating at the milestone-heavy pharma end and the direct-to-consumer end instead.
The FDA Moves Fast on AI Devices. The EU Just Pushed Its Deadline to 2028.
The United States and the European Union are running two different regulatory clocks on AI-enabled genomics tools, and the gap between them widened in 2026. The FDA's framework for AI and machine learning in software as a medical device now includes a December 2024 final guidance on Predetermined Change Control Plans, letting device makers pre-authorize algorithm updates instead of filing a new submission every time a model improves, built on Good Machine Learning Practice principles the FDA established jointly with Health Canada and the UK's MHRA in 2021.
The EU AI Act takes a different shape. Article 6 of the Act classifies an AI system as high-risk when it functions as a safety component of a product, including genomics-based companion diagnostics, requiring third-party conformity assessment under existing EU product-safety law, with obligations covering risk management, technical documentation, and database registration.
That compliance timeline keeps moving, though. The European Commission's 2026 Digital Omnibus on AI pushed the deadline for high-risk systems embedded in regulated products, the category genomics diagnostics fall into, to August 2, 2028, and stand-alone high-risk systems to December 2, 2027, both later than the August 2026 date vendors planned around last year. Genomics companies now have more runway in Europe than expected.
What Biotech CIOs and Instrument Vendors Should Actually Do Before 2028
Two executive audiences need to act on different timelines here. Biotech and pharma R&D and IT leaders should build Predetermined Change Control Plan-ready documentation now, even though the EU deadline moved, because the FDA's iterative-update pathway already rewards teams with Good Machine Learning Practice-aligned data governance in place. That documentation work also pays off in Europe eventually, since the underlying risk management and technical-documentation obligations under Article 6 are not going away, only the enforcement date. Waiting for a regulatory deadline that just got pushed back two years is a way to lose the U.S. speed advantage without gaining anything in Europe.
Sequencing instrument vendors and bioinformatics software companies face a sharper choice. Kaiso Research's own segmentation puts software ahead of hardware as the dominant component category in this market, which means a hardware-only roadmap concedes the highest-margin layer to whoever the customer's AI partner happens to be, whether that is NVIDIA, Google, or someone else entirely. The decision is binary: vertically integrate the way Illumina did, or specialize defensibly the way QIAGEN has through acquisition, because the middle ground, selling sequencing hardware with no AI layer attached, is shrinking. Bioinformatics vendors without a hardware or hyperscaler partner by the next product cycle will spend the following two to three years negotiating pricing on someone else's terms.
Three Bottlenecks That Could Slow the 46.0% CAGR: Talent, Privacy, and Legacy Systems
Three structural risks sit underneath Kaiso Research's forecast, and none of them are about whether the underlying AI models work. The first is a talent bottleneck: few professionals combine genomics domain depth with deep learning engineering skill, and computational genomics training pipelines graduate far fewer specialists each year than Illumina, QIAGEN, and major pharma R&D units combined currently need.
The second is a policy conflict between data sovereignty and cloud-native AI training. GDPR in Europe and emerging data-localization requirements elsewhere keep genomic datasets inside national borders, colliding directly with the cloud-native, elastic-compute deployment model that makes training AI on large, pooled cohorts economically viable in the first place. Explainable AI sounds like a compliance checkbox until a clinician has to justify a treatment decision to a malpractice attorney using a model's output as evidence, and that is precisely where data-sovereignty rules and explainability requirements collide right now.
The third is integration debt. AI-genomics platforms are built for real-time API calls and cloud-native pipelines, but they still have to interface with decades-old hospital and reference-lab systems never designed for that kind of traffic. That integration work, not the AI model itself, is usually what stretches a clinical deployment timeline from a pilot measured in months to a rollout measured in years.
Where the AI in Genomics Market Lands by 2035, and Where It Does Not
Kaiso Research's forecast carries the global AI in genomics market from $1,061.32 million in 2024 to $68,191.11 million by 2035, a 46.0% CAGR sustained over a full decade rather than a short adoption spike. That arc assumes software keeps the dominant component share it holds today, sequencing volume keeps outpacing manual interpretation capacity, and the regulatory pathways now being negotiated in Washington and Brussels land at clearance rather than gridlock. None of that is guaranteed evenly across all eleven years. The 46.0% figure is a software-led number, not a hardware-led one, and the segmentation data underneath it does not let hardware-only vendors borrow that growth rate for their own roadmaps.
The Software Premium Is Already Priced In. The Hardware Premium Is Not.
None of this required a hardware breakthrough. Illumina didn't need a faster sequencer to partner with NVIDIA. QIAGEN didn't need a new instrument to acquire Parse Biosciences. Google DeepMind didn't sequence a single new genome to build AlphaGenome.
Every structural move described here happened at the interpretation layer, on top of sequencing infrastructure that, in most cases, was already years old. The capital, the regulatory filings, and the partnership announcements all landed on software, on models, and on data rights, not on a single new instrument. That is the detail vendors selling sequencing hardware on a 2035 horizon need to sit with.
Kaiso Research's segmentation puts software ahead of hardware today, and nothing in the regulatory timeline, the funding pattern, or the partnership structure of the last eighteen months suggests that gap closes. It widens. The instrument got the genomics industry to the data. The model is what gets paid for understanding it.
----
About Kaiso Research and Consulting
Kaiso Research and Consulting is a global market intelligence firm publishing 5,000+ research reports across 11+ industry verticals.
kaisoresearch.com | [email protected] | +1 872 219 0417
Isha Paliwal, Lead Industry Analyst, Kaiso Research and Consulting | Covering AI-enabled genomics and precision medicine across North America, Europe, Asia-Pacific, and LAMEA
Published: 2026-06-29 | Report Code: LSDB14
Market Study: Access the full index or request a complimentary sample directly via the Global AI in Genomics Market Size, Trend & Opportunity Analysis Report page
